Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Form 8 (OPD)

17 Dec 2019 16:36

RNS Number : 2213X
Open Orphan PLC
17 December 2019
 

The Form 8 announcement released on 17/12/19 at 10:19 under RNS No 0632X has been amended.

 

The full amended text is shown below.

 

Open Orphan plc

 

("Open Orphan" or the "Company")

 

Disclosure under rule 8.1 and 8.2 of the Takeover Code

 

In accordance with Takeover code rule 8.1, the Company makes the following announcement:

 

 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Open Orphan plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Open Orphan plc

(d) Is the discloser the offeror or the offeree?

OFFEROR

(e) Date position held:

The latest practicable date prior to the disclosure

13 December 2019

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary Shares of 0.1p each

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

None

None

(2) Cash-settled derivatives:

 

None

None

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

None

None

 

TOTAL:

None

None

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Details of Concert Party shareholdings:

 

Current

% of current total

Raglan Road Capital Limited

21,536,124

8.46%

Pamela Iver

14,880,721

5.85%

Horizon Medical Technologies Limited

4,630,136

1.82%

Anthony Richardson

16,313,388

6.41%

Brendan Buckley

7,845,860

3.08%

Crow Rock Capital Limited

7,845,860

3.08%

Dairine Dempsey

3,138,344

1.23%

Ian O'Connell

3,138,344

1.23%

Montana Capital Limited

1,376,466

0.54%

Clydagh Limited

1,376,466

0.54%

Pat O'Neill

1,569,172

0.62%

McNolan Ventures Limited

470,974

0.19%

Carol Dalton

313,983

0.12%

Bridget Chisolm

313,983

0.12%

Ross Crocket

313,983

0.12%

Dennis Jennings

1,003,332

0.39%

Tom Tierney

2,006,665

0.79%

Mount Amber International Limited

5,016,291

1.97%

Francoise Richardson

1,805,136

0.71%

Gary Duffy

539,654

0.21%

 

 

 

Details of concert party options/warrants:

 

Options over Open Orphan shares

Raglan Road Capital Limited

3,250,000

Cathal Friel CMF Pension Fund

657,285

Dan Cronin

539,654

Michael Fleming

269,866

Pa Nolan

269,866

Maurice Treacy*

7,716,964

 

Details of Director shareholdings (excluding those in the Concert Party)

 

Options over Open Orphan shares

Michael Ryan

134,586

 

 

Details of Director options (excluding those in the Concert Party)

 

Options over Open Orphan shares

Grant date

Exercise price per share (pence)

Expiry date

Christian Milla

770,000

14/09/2017

13

13/09/2027

Michael Ryan

200,000

14/09/2017

13

13/09/2027

 

*Maurice Treacy's options were granted on 28/06/2019, with an exercise price per share of 5.6 pence and expiry date of 27/06/2022

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

17 December 2019

Contact name:

Cathal Friel, Chief Executive Officer

Telephone number:

+353 (0)1 644 0007

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEEFMMMZVNFGLZM
Date   Source Headline
30th Jan 201511:57 amRNSHolding(s) in Company
28th Jan 201512:05 pmRNSGrant of Options
6th Jan 20157:00 amRNSDirectorate Change
23rd Dec 20147:00 amRNSYear End Update
10th Dec 20147:00 amRNSInnovenn Board Appointment
20th Nov 20147:00 amRNSInnovenn commences production at new facilities
11th Nov 20147:00 amRNSEUR1.4m contract win with US firm
21st Oct 20147:00 amRNSEUR1.2m Contract with Global Pharmaceutical Comp
30th Sep 20147:01 amRNSStrategic Investment in InnoVenn
30th Sep 20147:00 amRNSInterim Results
18th Sep 201411:29 amRNSHolding(s) in Company
8th Sep 20143:00 pmRNSIssue of Consideration Shares
8th Sep 20147:00 amRNSEUR2.4m contract for pan-European coronary study
5th Aug 20147:00 amRNSAcquisition of French CRO
24th Jun 20143:44 pmRNSResult of AGM
24th Jun 20147:00 amRNSAGM Statement
19th Jun 20147:00 amRNSSkin science patent grant
27th May 20142:26 pmRNSDirector's Dealing
16th May 201412:25 pmRNSMajor contract win
16th May 201412:23 pmRNSFinal Results
2nd Apr 201412:21 pmRNSHolding(s) in Company
31st Mar 201411:48 amRNSResult of general meeting
18th Mar 20142:46 pmRNSUpdate on the Acquisition of Evocutis plc
14th Mar 20147:00 amRNSPlacing to raise £1 million & Notice of GM
13th Mar 20141:00 pmRNSUpdate of Evocutis plc acquisition
13th Mar 20141:00 pmRNSResult of AGM and General Meeting
26th Feb 20147:00 amRNSAcquisition of the trading assets of Evocutis PLC
26th Feb 20147:00 amRNSCirc re. Disposal and Notice of GM
13th Jan 20147:00 amRNSUpdate re: Aquisition of German based CRO
9th Dec 20137:00 amRNSAcquisition of Belfast Based CRO
29th Nov 201312:16 pmRNSHolding(s) in Company
31st Oct 20137:00 amRNSAcquisition
11th Oct 20131:31 pmRNSHolding(s) in Company
3rd Oct 201312:55 pmRNSDirector's Dealing
2nd Oct 20132:17 pmRNSChange of Registered Office
27th Sep 20137:00 amRNSInterim Results
23rd Jul 20133:39 pmRNSResult of AGM
13th Jun 20137:00 amRNSFinal Results
17th May 20137:00 amRNSInnovation division launch & co-development
7th May 20138:36 amRNSHolding(s) in Company
26th Apr 20137:09 amRNSProject wins
9th Apr 20137:00 amRNSSenior Management Appointments
14th Mar 20137:00 amRNSBoard Appointment
5th Mar 20131:19 pmRNSHolding(s) in Company
28th Feb 201312:47 pmRNSDirector/PDMR Shareholding
21st Feb 20139:49 amRNSDirector/PDMR Shareholding
7th Feb 20137:00 amRNSVenn Life Sciences expands into Russia
14th Dec 20127:00 amRNSAdmission to trading on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.